Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for ...

FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in ...

Milestone Pharmaceuticals Q4 Earnings Call Highlights

Milestone Pharmaceuticals (NASDAQ:MIST) executives highlighted the company’s transition to commercialization during a ...